II. Definitions
- QT Interval
- EKG interval between the begining of the QRS interval and the end of the T Wave
- Represents ventricular electrical activity (from ventricular depolarization to repolarization)
III. Interpretation: Normal QT Duration
- Always confirm Prolonged QT with a manual measurement (QTc >500 ms)
- Computer read EKG can over-measure QTc (e.g. in presence of U Waves)
- QT modifying factors
- Normal QT decreases with increasing Heart Rate
- QT is longer in leads V2 and v3
- Calculation of QTc or corrected QT (Bazett's Formula)
- QTc = QT/(sqrt RR Interval)
- QTc is normally <0.45 in men (<0.46 in women and children)
- Prolonged QTc (esp. >0.5) is at risk of Torsades de Pointes (see below)
- Approximation of normal QT
- QT Interval shortens with decreasing RR Interval
- QT = 0.5 x preceding RR Interval (if normal rate, 60 to 100 bpm)
- QT should be less than half the duration of the R-R interval (rate 60 to 100 bpm)
- Approximate normal QT Interval
- QT <= 0.38 if Heart Rate 80 bpm or greater
- Add 0.02 sec for every 10 bpm below 80
- Example: Normal QT <= 0.46 if Heart Rate 40-50
-
Heart Rate determined QT
- 115 - 84 bpm: QT 0.30 to 0.37 seconds
- 83 - 72 bpm: QT 0.32 to 0.40 seconds
- 71 - 63 bpm: QT 0.34 to 0.42 seconds
- 62 - 56 bpm: QT 0.36 to 0.43 seconds
- 55 - 45 bpm: QT 0.39 to 0.46 seconds
IV. Causes: Prolonged QT (QTc > 500 ms)
- See Prolonged QT Interval due to Medication
- Familial Long QT Syndrome (congenital Prolonged QT, cardiac ion channel abnormalities)
- Congestive Heart Failure
- Cardiomyopathy
- Myocardial Infarction
- Hypocalcemia
- Hypokalemia
- Hypomagnesemia
- Type I Antiarrhythmic drugs (Sodium channel blocking drugs)
- Rheumatic Fever
- Myocarditis
- Congenital Heart Disease
- Hypothermia
- Increased Intracranial Pressure
-
Subarachnoid Hemorrhage (SAH)
- Mechanism thought related to SAH induced Catecholamine surge
V. Complications: QT Prolongation resulting in Torsades de Pointes
- See Torsades de Pointes for management
- QT Prolongation risks R-On-T Phenomenon (PVC on T Wave) provoking polymorphic VT (Torsades)
- Consider baseline EKG prior to administering medications that may increase QTc
- Caution in patients with pre-existing QT Prolongation (QTc >450 ms) when prescribing new medications
- See Prolonged QT Interval due to Medication
- Select medications that do not prolong the QT Interval further
- Stop medication causes of Prolonged QT when QTc rises above 500 ms
- Avoid Beta Blockers, due to Syncope risk, precipitating Torsades (3.6 fold increased risk)
- Not all Prolonged QT intervals significantly predispose to Torsades
- Degree of QT Prolongation does not correlate with risk of Torsades
- Medication specific effects (e.g. some medications are more likely to result in Torsades)
- See Prolonged QT Interval due to Medication for likelihood of Torsades
- Avoid combining multiple medications each of which increase QT Interval
- Coexisting conditions which make Drug-Induced Torsades de Pointes more likely
- Baseline QT Prolongation
- Bradycardia
- Acute Myocardial Infarction
- Low Ejection Fraction
- Hypokalemia
- Hypomagnesemia
- Hypocalcemia
- Volume depletion (Vomiting, Diuretics)
- Female gender (long QT Interval at baseline)
- Evaluate context of QT Prolongation
- QT Prolongation and reassuring findings that require no change in regimen
- Chronic, stable, asymptomatic use of a medication associated with QT Prolongation
- QT Prolongation and red flag findings that suggest further evaluation or regimen change
- Family History of Sudden Cardiac Death
- Symptoms (high risk group that requires thorough evaluation)
- Syncope
- Palpitations
- Spells or Seizures (presenting event in 10% of pediatric cases)
- QT Prolongation and reassuring findings that require no change in regimen
VI. Causes: Shortened QT (<330 ms)
- Digoxin (Digitalis)
- Hypercalcemia
- Hyperkalemia
- Phenothiazines
- Sympathomimetics
- Familial (cardiac ion channel abnormalities)
VII. Complications: Shortened QT (<330 ms)
- Syncope
- Paroxysmal Atrial Fibrillation
- Ventricular Fibrillation
VIII. References
- Joshi and Dermark (2016) Crit Dec Emerg Med 30(8):3-12
- Mirvis in Braunwald (2001) Cardiovascular, p. 92-3
- Rollings (1984) Facts and Formulas, p. 64